A carregar...

Critical appraisal of cabazitaxel in the management of advanced prostate cancer

Docetaxel remains a cornerstone of therapy for the patient with metastatic castration-resistant prostate cancer (CRPC). However, the landscape of CRPC therapy is changing rapidly – recently, data from the phase III TROPIC study revealed a survival advantage with the novel taxane cabazitaxel/predniso...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Pal, Sumanta Kumar, Twardowski, Przemyslaw, Sartor, Oliver
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2010
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2998247/
https://ncbi.nlm.nih.gov/pubmed/21152241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CIA.S14570
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!